The antiemetic prophylaxis for the PONV (postoperative nausea and vomiting) in patients undergoing microvascular decompression: a prospective randomized controlled trial

The antiemetic prophylaxis for the PONV (postoperative nausea and vomiting) in patients undergoing microvascular decompression: a prospective randomized controlled trial - PONV prevention in patients undergoing MVD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000040178

Enrollment

100

Registered

2020-04-16

Start date

2020-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Intervention: Ramosetron (0.3 mg) is administered at the end of surgery Control: Normal saline 1cc is administered at the end of surgery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who undergo elective microvascular decompression American Society of anesthesiologists grade 1 or 2 Patients > 19 years

Exclusion criteria

Exclusion criteria: Refuse to participate to the study Body Mass Index < 18.5 or > 35 kg/m2 History of craniotomy History of chemotherapy History of preoperative antiemetics Severe renal or hepatic dysfunction Chronic opioid use Prolonged QTc (>450ms)

Design outcomes

Primary

Measure	Time frame
The incidence of postoperative nausea and vomiting (PONV) at postoperative 48 hours	—

Secondary

Measure	Time frame
The severity of PONV antiemetics requirements PCA consumption Length of hospital stay	—

Countries

Asia(except Japan)

Contacts

Public ContactChang-Hoon Koo

Seoul National University Bundang Hospital Department of Anesthesiology and Pain medicine

vollock9@gmail.com+82-31-787-3659

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026